Point72 Asset Management
ADMA icon

Point72 Asset Management’s ADMA Biologics ADMA Stock Holding History

Point72 Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$188K Sell
20,900
-26,300
-56% -$415K ﹤0.01% 3538
2025
Q4 		$861K Buy
+47,200
New +$796K ﹤0.01% 2950
2025
Q2 		– Sell
-300,000
Closed -$5.95M – 2131
2025
Q1 		$5.95M Buy
+300,000
New +$5.19M 0.01% 862

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Point72 Asset Management's ADMA Position: Q1 2026 in Review

Point72 Asset Management increased its ADMA Biologics (ADMA) stake by 735% in Q1 2026, buying an estimated $45.7M and bringing the position to 3,288,757 shares worth $29.6M. The position accounts for 0.04% of the portfolio, ranked #614.

Point72 Asset Management first reported a position in ADMA in Q1 2020 and has held it in 11 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Point72 Asset Management held 3,288,757 shares of ADMA Biologics worth $29.6M as of Q1 2026.
  • Point72 Asset Management bought 2,894,878 ADMA Biologics shares in Q1 2026, an estimated $45.7M.
  • ADMA Biologics made up 0.04% of Point72 Asset Management's portfolio in Q1 2026, its #614 holding.
  • Point72 Asset Management first reported a position in ADMA Biologics in Q1 2020 and has held it in 11 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.